Masataka Ikeda

Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201)

M. Kusano, J. Sakamoto, I. Hyodo, 2022, BMC Cancer.

Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: The FUGA-BT (JCOG1113) Randomized Phase III Clinical Trial.

H. Katayama, J. Furuse, N. Kato, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin

H. Ueno, Y. Shimada, K. Muro, 2004, British Journal of Cancer.

Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer

G. Wakabayashi, M. Unno, I. Hyodo, 2015, British Journal of Cancer.

3544 POSTER Phase I study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy in gemcitabine-refractory pancreatic cancer patients.

H. Ueno, J. Furuse, M. Ikeda, 2007 .

A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.

H. Ueno, J. Furuse, M. Ikeda, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation

T. Okusaka, T. Hamaguchi, K. Shirao, 2007, British Journal of Cancer.

Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer

H. Ueno, M. Ikeda, T. Okusaka, 2004, British Journal of Cancer.